Biological
rgp120/HIV-1IIIB clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
How studies write it
Studies that test it under each name
Name
- rgp120/HIV-1IIIB
- 3
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Genentech, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rgp120/HIV-1IIIB is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001020Written as rgp120/HIV-1IIIB
- A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult VolunteersCompletedPhase 1Genentech, Inc.NCT00001992Written as rgp120/HIV-1IIIB
- A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001021Written as rgp120/HIV-1IIIB